|
Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue Clinical research trials and Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue. Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue clinical trial. Human subjects often obtain the finest healthcare possible for their Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue  Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue
Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue
For Condition: unspecified adult solid tumor, protocol specific,Anemia,Fatigue
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Robert H. Lurie Cancer Center
Synopsis: RATIONALE: Exercise may decrease anemia -related fatigue, improve strength, and build up lost muscle tissue. Epoetin alfa may help improve cancer-related anemia, energy levels, and quality of life. Exercise plus epoetin alfa may be effective treatment for anemia-related fatigue. PURPOSE: Phase II trial to study the effectiveness of exercise plus epoetin alfa in treating cancer patients who have anemia-related fatigue.
Details: OBJECTIVES: I. Determine the effect of progressive resistance training and epoetin alfa on lean body mass, fatigue, exercise tolerance, functional capacity, and total body weight in cancer patients with anemia related fatigue. PROTOCOL OUTLINE: Patients undergo progressive resistance training (PRT) consisting of 3 sets of 8 repetitions of concentric (lifting) and eccentric (lowering) exercises over 4-6 seconds each using bench press, arm pull, knee extension, knee flexion, and double leg press followed by 1-2 minutes of rest between sets. Patients undergo warm up and cool down periods over 10 minutes prior to and following PRT. Patients perform PRT 3 times a week for 12 weeks. Patients also receive epoetin alfa subcutaneously once weekly over 4-12 weeks in the absence of unacceptable toxicity. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study over 15 months.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of nonmyeloid malignancy with cancer related fatigue - Anemia (hemoglobin less than 10 g/dL) - No clinical or radiographic evidence of lytic bone metastases --Prior/Concurrent Therapy-- - Biologic therapy: At least 8 weeks since prior epoetin alfa - Chemotherapy: Concurrent chemotherapy allowed - Endocrine therapy: Not specified - Radiotherapy: Concurrent radiotherapy allowed - Surgery: Not specified - Other: Concurrent anticancer therapy allowed; At least 1 month since prior strength training of greater than 3 hours a week --Patient Characteristics-- - Age: Over 18 - Performance status: ECOG 0-2 - Life expectancy: Greater than 4 months - Hematopoietic: See Disease Characteristics - Hepatic: Not specified - Renal: Not specified - Other: No dementia or evidence of mental incompetence; No physical handicap precluding aerobic or resistance exercise; No clinical abnormality that would render exercise a risk; HIV negative; No contraindications to epoetin alfa; Not pregnant or nursing; Negative pregnancy test
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JamieVon Roenn, Study Chair, Robert H. Lurie Cancer Center
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611-3013
United States
Additional Information:
Study ID Numbers: CDR0000067594; NU-98CC7,NCI-G00-1706
Study Start Date: January 2000
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004914
Other Fatigue Studies:
1. CHS 828 in Treating Patients With Solid Tumors
2. Continuous Infusion Gemcitabine in Treating Patients With Advanced Metastatic Cancer
3. Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction
4. Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors
5. Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors
Related Studies:
Other Fatigue Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue
|
|
|
|
|
|
|
|
